Alzheimer-Demenz: Neurobiologie, Diagnostik und experimentelle Ansätze

Liquormarker und bildgebende Verfahren helfen bei der Stellung der Diagnose der Alzheimer-Demenz (AD), die sich aktuell nur anhand histopathologischer Charakteristika definitiv sichern lässt. Letztere sind bereits vor Symptomentwicklung nachweisbar, weshalb die Identifikation von Biomarkern zur Früherkennung der derzeit nicht kausal behandelbaren, AD angestrebt wird, um den rechtzeitigen Einsatz von präventiven Therapien zu ermöglichen.

Schlüsselwörter

Diagnostik der Alzheimer-Demenz - Klassifikationssysteme für die Diagnostik - Pathophysiologie - Früherkennung

• Literatur

• 1 DGPPN, DGN. Allgemeine Grundlagen. In: DGPPN – DGN, Hrsg. S3-Leitlinie Demenzen. Berlin, Heidelberg: Springer; 2017: 13-34
• 2 Livingston G, Sommerlad A, Orgeta V. et al. Dementia prevention, intervention, and care. Lancet 2017; 390: 2673-2734 doi:10.1016/S0140-6736(17)31363-6
• 3 Dilling H. Weltgesundheitsorganisation. Hrsg. Internationale Klassifikation psychischer Störungen: ICD-10 Kapitel V (F); klinisch-diagnostische Leitlinien. 5. Aufl. unter Berücksichtigung der Änderungen entsprechend ICD-10-GM 2004/2005. Bern: Huber; 2005
• 4 Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci 2015; 16: 358-372 doi:10.1038/nrn3880
• 5 Shi Y, Holtzman DM. Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. Nat Rev Immunol 2018;
• 6 Kumar K, Kumar A, Keegan RM. et al. Recent advances in the neurobiology and neuropharmacology of Alzheimerʼs disease. Biomed Pharmacother 2018; 98: 297-307 doi:10.1016/j.biopha.2017.12.053
• 7 Gonzalez B, Abud EM, Abud AM. et al. Tau spread, Apolipoprotein E, inflammation, and more. Neurol Clin 2017; 35: 175-190 doi:10.1016/j.ncl.2017.01.001
• 8 Gorantla NV, Chinnathambi S. Tau protein squired by molecular chaperones during Alzheimerʼs disease. J Mol Neurosci MN 2018;
• 9 Bloom GS. Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol 2014; 71: 505 doi:10.1001/jamaneurol.2013.5847
• 10 Naj AC, Schellenberg GD. Alzheimerʼs Disease Genetics Consortium (ADGC). Genomic variants, genes, and pathways of Alzheimerʼs disease: An overview. Am J Med Genet B Neuropsychiatr Genet 2017; 174: 5-26 doi:10.1002/ajmg.b.32499
• 11 Tosto G, Bird TD, Tsuang D. et al. Polygenic risk scores in familial Alzheimer disease. Neurology 2017; 88: 1180-1186 doi:10.1212/WNL.0000000000003734
• 12 Schmidt U, Vermetten E. Integrating NIMH Research Domain Criteria (RDoC) into PTSD Research. In: Vermetten E, Baker DG, Risbrough VB, eds. Behavioral Neurobiology of PTSD. Cham: Springer International Publishing; 2017: 69-91
• 13 Barrachina M, Ferrer I. DNA methylation of Alzheimer disease and tauopathy-related genes in postmortem brain. J Neuropathol Exp Neurol 2009; 68: 880-891 doi:10.1097/NEN.0b013e3181af2e46
• 14 Nativio R, Donahue G, Berson A. et al. Dysregulation of the epigenetic landscape of normal aging in Alzheimerʼs disease. Nat Neurosci 2018; 21: 497-505 doi:10.1038/s41593-018-0101-9
• 15 Prasad H, Rao R. Amyloid clearance defect in ApoE4 astrocytes is reversed by epigenetic correction of endosomal pH. Proc Natl Acad Sci U S A 2018; 115: E6640-E6649 doi:10.1073/pnas.1801612115
• 16 Agís-Balboa RC, Pinheiro PS, Rebola N. et al. Formin 2 links neuropsychiatric phenotypes at young age to an increased risk for dementia. EMBO J 2017; 36: 2815-2828 doi:10.15252/embj.201796821
• 17 Fliessbach K, Schneider A. Biomarker-basierte Diagnostik der Alzheimer-Krankheit: Konzept der „suspected non-Alzheimer pathology“. Nervenarzt 2018; 89: 345-358 doi:10.1007/s00115-018-0488-2
• 18 McKhann GM, Knopman DS, Chertkow H. et al. The diagnosis of dementia due to Alzheimerʼs disease: recommendations from the National Institute on Aging-Alzheimerʼs Association workgroups on diagnostic guidelines for Alzheimerʼs disease. Alzheimers Dement 2011; 7: 263-269 doi:10.1016/j.jalz.2011.03.005
• 19 Jack CR, Bennett DA, Blennow K. et al. NIA-AA Research Framework: Toward a biological definition of Alzheimerʼs disease. Alzheimers Dement 2018; 14: 535-562 doi:10.1016/j.jalz.2018.02.018
• 20 Dubois B, Feldman HH, Jacova C. et al. Advancing research diagnostic criteria for Alzheimerʼs disease: the IWG-2 criteria. Lancet Neurol 2014; 13: 614-629 doi:10.1016/S1474-4422(14)70090-0
• 21 Baldeiras I, Santana I, Leitão MJ. et al. Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimerʼs disease dementia in mild cognitive impairment. Alzheimers Res Ther 2018; 10: 33 doi:10.1186/s13195-018-0362-2
• 22 Nakamura A, Kaneko N, Villemagne VL. et al. High performance plasma amyloid-β biomarkers for Alzheimerʼs disease. Nature 2018; 554: 249-254 doi:10.1038/nature25456
• 23 Klafki HW, Hafermann H, Bauer C. et al. Validation of a commercial chemiluminescence immunoassay for the simultaneous measurement of three different amyloid-β peptides in human cerebrospinal fluid and application to a clinical cohort. J Alzheimers Dis 2016; 54: 691-705 doi:10.3233/JAD-160398
• 24 Nabers A, Ollesch J, Schartner J. et al. Amyloid-β-secondary structure distribution in cerebrospinal fluid and blood measured by an immuno-infrared-sensor: A biomarker candidate for Alzheimerʼs disease. Anal Chem 2016; 88: 2755-2762 doi:10.1021/acs.analchem.5b04286
• 25 Graham WV, Bonito-Oliva A, Sakmar TP. Update on Alzheimerʼs disease therapy and prevention strategies. Annu Rev Med 2017; 68: 413-430 doi:10.1146/annurev-med-042915-103753